HBK Sorce Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.24M Buy
39,824
+1,078
+3% +$62.8K 0.04% 143
2025
Q4
$2.4M Buy
38,746
+451
+1% +$21.7K 0.06% 141
2025
Q3
$1.67M Buy
38,295
+2,472
+7% +$115K 0.04% 159
2025
Q2
$1.66M Sell
35,823
-873
-2% -$42.9K 0.04% 157
2025
Q1
$2.24M Buy
36,696
+2,232
+6% +$130K 0.07% 122
2024
Q4
$1.95M Sell
34,464
-459
-1% -$25.6K 0.06% 137
2024
Q3
$1.81M Buy
34,923
+3,379
+11% +$159K 0.06% 144
2024
Q2
$1.31M Sell
31,544
-1,034
-3% -$46.3K 0.05% 176
2024
Q1
$1.77M Buy
32,578
+1,159
+4% +$59K 0.06% 154
2023
Q4
$1.61M Sell
31,419
-3,675
-10% -$193K 0.06% 159
2023
Q3
$2.04M Buy
35,094
+19
+0.1% +$1.16K 0.09% 131
2023
Q2
$2.24M Sell
35,075
-3,482
-9% -$233K 0.09% 128
2023
Q1
$2.67M Sell
38,557
-35,417
-48% -$2.5M 0.12% 111
2022
Q4
$5.32M Buy
73,974
+40,243
+119% +$3.03M 0.14% 102
2022
Q3
$2.4M Buy
33,731
+5,459
+19% +$396K 0.16% 100
2022
Q2
$2.18M Sell
28,272
-6,338
-18% -$483K 0.16% 97
2022
Q1
$2.53M Sell
34,610
-330
-0.9% -$22.2K 0.14% 108
2021
Q4
$2.18M Sell
34,940
-31
-0.1% -$1.82K 0.11% 132
2021
Q3
$2.07M Sell
34,971
-1,895
-5% -$125K 0.11% 128
2021
Q2
$2.46M Sell
36,866
-466
-1% -$30.4K 0.14% 114
2021
Q1
$2.36M Buy
37,332
+529
+1% +$32.9K 0.14% 110
2020
Q4
$2.28M Sell
36,803
-65
-0.2% -$4K 0.14% 107
2020
Q3
$2.22M Buy
36,868
+1,136
+3% +$68.4K 0.16% 93
2020
Q2
$2.1M Buy
35,732
+7,890
+28% +$472K 0.16% 96
2020
Q1
$1.55M Sell
27,842
-1,103
-4% -$67.4K 0.15% 101
2019
Q4
$1.86M Buy
28,945
+3,282
+13% +$188K 0.16% 107
2019
Q3
$1.3M Sell
25,663
-1,297
-5% -$61K 0.12% 124
2019
Q2
$1.22M Sell
26,960
-4,273
-14% -$199K 0.12% 133
2019
Q1
$1.49M Buy
31,233
+9,993
+47% +$498K 0.15% 115
2018
Q4
$1.1M Sell
21,240
-255
-1% -$13.7K 0.13% 135
2018
Q3
$1.33M Sell
21,495
-713
-3% -$42.3K 0.15% 104
2018
Q2
$1.23M Sell
22,208
-691
-3% -$37.3K 0.14% 110
2018
Q1
$1.45M Buy
22,899
+552
+2% +$35.5K 0.18% 93
2017
Q4
$1.37M Buy
22,347
+5,028
+29% +$314K 0.16% 100
2017
Q3
$1.1M Buy
17,319
+981
+6% +$57.3K 0.17% 89
2017
Q2
$910K Buy
+16,338
New +$889K 0.15% 103
2017
Q1
Sell
-16,207
Closed -$889K 318
2016
Q4
$947K Buy
16,207
+171
+1% +$9.35K 0.17% 96
2016
Q3
$865K Buy
16,036
+3,143
+24% +$202K 0.17% 89
2016
Q2
$948K Buy
12,893
+2,590
+25% +$183K 0.2% 83
2016
Q1
$658K Buy
10,303
+2,931
+40% +$185K 0.16% 95
2015
Q4
$507K Buy
7,372
+74
+1% +$4.89K 0.13% 111
2015
Q3
$432K Buy
7,298
+202
+3% +$12.8K 0.14% 104
2015
Q2
$472K Sell
7,096
-31
-0.4% -$2.04K 0.16% 102
2015
Q1
$460K Sell
7,127
-531
-7% -$33.2K 0.16% 100
2014
Q4
$452K Sell
7,658
-1,448
-16% -$81.7K 0.16% 105
2014
Q3
$466K Buy
9,106
+747
+9% +$37.3K 0.17% 87
2014
Q2
$406K Sell
8,359
-1,749
-17% -$86.2K 0.14% 99
2014
Q1
$525K Buy
10,108
+3,344
+49% +$178K 0.19% 81
2013
Q4
$359K Buy
6,764
+4
+0.1% +$204 0.13% 105
2013
Q3
$313K Sell
6,760
-6,780
-50% -$298K 0.13% 115
2013
Q2
$606K Buy
+13,540
New +$588K 0.13% 112

Other funds holding BMY

HBK Sorce Advisory's BMY Position: Q1 2026 in Review

HBK Sorce Advisory increased its Bristol-Myers Squibb (BMY) stake by 2.8% in Q1 2026, buying an estimated $62.8K and bringing the position to 39,824 shares worth $2.24M. The position accounts for 0.04% of the portfolio, ranked #143.

HBK Sorce Advisory first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.32M in Q4 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • HBK Sorce Advisory held 39,824 shares of Bristol-Myers Squibb worth $2.24M as of Q1 2026.
  • HBK Sorce Advisory bought 1,078 Bristol-Myers Squibb shares in Q1 2026, an estimated $62.8K.
  • Bristol-Myers Squibb made up 0.04% of HBK Sorce Advisory's portfolio in Q1 2026, its #143 holding.
  • HBK Sorce Advisory first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
  • HBK Sorce Advisory's Bristol-Myers Squibb position peaked at $5.32M in Q4 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.